Inoviv is pleased to bring together leading drug developers and industry experts to discuss NeuroKey-3™, a recent advancement in disease-targeted LC-MS biomarker assays for coverage of key Alzheimer’s disease (AD) and Dementia markers in human plasma. The discussion will be led by Inoviv’s Commercial SVP, Ben Gonzales, and Chief Scientific Officer, Ernestas Sirka.


Current treatments for neurodegenerative diseases are restricted. The advancement of effective medicines, including efficacy assessment beyond traditional cognitive tests, heavily relies on an optimal biomarker strategy for disease identification, monitoring, and stratification. However, current assays are costly to develop and validate, with levels that do not meet regulatory submission criteria.


To address these challenges, Inoviv developed NeuroKey-3™, a proprietary fully quantitative multiplexed IP-MS assay that utilizes novel workflows, to provide unparalleled reproducibility, robustness, and sensitivity in human plasma to help support clinical trials.


During this webinar, our proteomics experts will:


    • Demonstrate how NeuroKey-3™ quantifies key neurodegeneration plasma biomarkers including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and more.


    • Discuss fully quantitative, multiplexed LC-MS biomarker analysis to support drug discovery and development.


    • Present case studies, describing how neurological therapeutic developers have harnessed NeuroKey-3™ to generate valuable molecular insights for their clinical programs.